Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic strategy for managing metabolic conditions. These naturally occurring molecules are secreted by the gut in response Semaglutide USA supplier to meal intake, stimulating insulin release and suppressing glucagon secretion. GLP-1 agents demonstrate promising therapeutic e